CDC Financial’s Inhibrx INBX Stock Holding History

CDC Financial’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.84M	Sell	30,000 -32,000	-52%	-$3.21M	1.19%	19
2026 Q1	$4.17M	Buy	+62,000	New	+$4.6M	2.65%	13

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CDC Financial's INBX Position: Q2 2026 in Review

CDC Financial increased its Inhibrx (INBX) stake by 13% in Q2 2026, buying an estimated $1.56M and bringing the position to 140,130 shares worth $13.3M. The position accounts for 5.56% of the portfolio, ranked #5.

CDC Financial first reported a position in INBX in Q4 2025 and has held it in 3 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

CDC Financial held 140,130 shares of Inhibrx worth $13.3M as of Q2 2026.
CDC Financial bought 15,600 Inhibrx shares in Q2 2026, an estimated $1.56M.
Inhibrx made up 5.56% of CDC Financial's portfolio in Q2 2026, its #5 holding.
CDC Financial first reported a position in Inhibrx in Q4 2025 and has held it in 3 quarters since.
163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on CDC Financial's 13F filing for Q2 2026, filed 14 Aug 2026.